NCT03220295View on ClinicalTrials.gov

Putative Cognitive Enhancer VU319

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 28, 2017

Primary Completion Date

October 30, 2019

Study Completion Date

October 30, 2019

Conditions
Cognitive Impairment
Interventions
DRUG

Single Dose of VU319

Single dose of VU319

DRUG

Single Dose Placebo

Single dose of placebo

OTHER

Fed State

drug is given 30 minutes after a high fat breakfast

OTHER

Fasted State

drug is given after an overnight fast

DRUG

Dose Escalation of VU319

dose levels of the cohorts will be increased step wise

DRUG

Placebo Dose Escalation

dose levels of the cohorts will be increased step wise

Trial Locations (1)

37212

Vanderbilt Medical Center, Nashville

All Listed Sponsors
collaborator

Vanderbilt University Medical Center

OTHER

lead

Vanderbilt University

OTHER

NCT03220295 - Putative Cognitive Enhancer VU319 | Biotech Hunter | Biotech Hunter